3 results
To assess the rates of preliminary response and sustained remission of AASV following rituximab (on the basis of former studies, 86% sustained remission expected with rituximab compared to 75% in control group).To assess safety of a rituximab…
Primary Objectives* Phase 1b lead-in: To assess safety and tolerability of a single dose level of avelumab in combination withincreasing dose levels of other immune modulators in combination with a single doselevel of avelumab in patients with…
The objective of this randomized noninferiority trial is to determine whether INTELLiVENT*ASV with sidestream capnography is noninferior to INTELLiVENT*ASV with mainstream capnography with regard to the percentage of breaths in a broadly accepted…